Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $164.8 million.

  • Crinetics Pharmaceuticals' Cash from Investing Activities rose 69992.72% to $164.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$425.3 million, marking a year-over-year decrease of 25429.66%. This contributed to the annual value of -$574.8 million for FY2024, which is 18681.62% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Cash from Investing Activities of $164.8 million as of Q3 2025, which was up 69992.72% from $38.0 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Cash from Investing Activities high stood at $164.8 million for Q3 2025, and its period low was -$542.1 million during Q4 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' median Cash from Investing Activities value was $309000.0 (recorded in 2024), while the average stood at -$46.8 million.
  • The largest annual percentage gain for Crinetics Pharmaceuticals' Cash from Investing Activities in the last 5 years was 69992.72% (2025), contrasted with its biggest fall of 2791909.39% (2025).
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Cash from Investing Activities stood at -$101.8 million in 2021, then skyrocketed by 136.2% to $36.9 million in 2022, then crashed by 336.91% to -$87.3 million in 2023, then tumbled by 520.89% to -$542.1 million in 2024, then skyrocketed by 130.4% to $164.8 million in 2025.
  • Its last three reported values are $164.8 million in Q3 2025, $38.0 million for Q2 2025, and -$86.0 million during Q1 2025.